The agreement sets terms under which POC will manufacture the product or receive royalties
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Combines biocompatibility, heat-resistance, transparency and durability
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Subscribe To Our Newsletter & Stay Updated
